It was with considerable pride I attended an ACOA announcement (https://www.canada.ca/en/atlantic-canada-opportunities/news/2019/04/nova-scotia-health-authority-making-strides-in-improving-orthopaedic-diagnostics-treatment.html) last week for $2 million in funding for the clinical deployment of new orthopaedic tools from Emovi Technologies, Kinduct Technologies, and our very own OrthoMX Technologies. OrthoMX, and my co-founder Dr. Michael Dunbar, have been collaborating with Emovi and Kinduct for almost 7 years and to see our collective dedication and persistence gain traction and move into clinical care is delightful. But even more meaningful is the promise of a single sign on solution for pre and post orthopaedic care that includes our InStride app, Emovi’s KneeKG diagnostic and is seamlessly delivered through Kinduct’s Clinic portal. Check out our innovations at www.instrideweb.com; www.emovi.ca and www.kinduct.com. You can also follow these three Canadian companies on Twitter: @orthomx, @knee_kg and @kinduct.
0 Comments
Leave a Reply. |
Barbara M. Campbell
For twenty years, writing business plans, funding applications and shareholder communications has been more my style than blogging. But here are a few tidbits I've learned along the way. Archives
June 2019
Categories |